AstraZeneca plc (AZN) Earns Buy Rating from Deutsche Bank AG
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Deutsche Bank AG in a research report issued to clients and investors on Tuesday. They currently have a GBX 6,200 ($76.73) price objective on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price would indicate a potential upside of 22.75% from the stock’s previous close.
Several other equities research analysts also recently issued reports on AZN. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Credit Suisse Group AG reiterated an “underperform” rating and set a GBX 4,000 ($49.50) price objective on shares of AstraZeneca plc in a research note on Wednesday, July 13th. Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, September 23rd. Goldman Sachs Group Inc. set a GBX 4,000 ($49.50) price objective on shares of AstraZeneca plc and gave the stock a “sell” rating in a research note on Wednesday, June 29th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 4,900 ($60.64) price objective on shares of AstraZeneca plc in a research note on Tuesday, August 23rd. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 4,937.91 ($61.11).
AstraZeneca plc (LON:AZN) opened at 5007.00 on Tuesday. The firm’s market capitalization is GBX 63.34 billion. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock has a 50 day moving average of GBX 5,004.92 and a 200 day moving average of GBX 4,463.08.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/astrazeneca-plc-azn-earns-buy-rating-from-deutsche-bank-ag-2.html
The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.85) dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.